Here, we developed a multichannel dialysis microchip having three sets of dialysis systems, which consisted of three independent circulation channels with a common micropump. Each dialysis system was composed of a pneumatic micropump (heart), dialysis unit (renal corpuscle), and cell culture chamber (drug target) as well as circulation and dialysate channels to mimic the circulation system. Small molecules were successfully separated in parallel from macromolecules at the dialysis components. Anticancer tests using this microchip showed results that considered both serum protein-binding nature and drug activity. In the anticancer bioassay, the multichannel chip showed similar reproducible and reliable results as those of the single-channel system but with higher throughput.
Introduction
Absorption, distribution, metabolism, and excretion (ADME) in pharmacokinetics are very important processes in drug development. For example, drug persistence is intimately related to the excretion portion of the ADME process, while drug residence time is evaluated by both in vitro and in vivo experiments. In these ADME studies, the fundamental properties of drugs are evaluated by in vitro experiments prior to in vivo animal experiments. However, animal experiments have been used less frequently over time because of species differences between humans and animals as well as ethical issues. 1 Therefore, novel in vitro assays substituting for animal experiments are needed.
In the microfluidic research field, many studies on the integration of analysis systems into a microchip, including bioassays with complicated processes, have been reported. 2, 3 In the last decade, the number of research studies on cell culture in a microchip has significantly increased. 4, 5 Especially, organ-ona-chip studies, which mimic the specific microenvironment of a human organ on a microchip, have attracted researchers' attention. Organ-on-a-chip studies have contributed to cell biology studies, 6, 7 e.g., control of cell differentiation and observation of cell-cell interactions.
In addition to the progress of organ-on-a-chip studies, the functions of several organs have been integrated into a single microchip to mimic the entire ADME process and named bodyon-a-chip or human-on-a-chip. [8] [9] [10] These studies are expected to serve as alternatives to animal tests in the near future. Organon-a-chip or body-on-a-chip systems are, however, in the proofof-concept stage, and many issues regarding their practical use remain to be improved. 11 Although many studies on micromodels of drug absorption or metabolic processes have been reported to date, 12-14 few organ-on-a-chip studies on drug excretion processes have been conducted. While many kidney-on-a-chip studies have been reported, most of them focused on the nephrotoxicity rather than renal excretion. 15 Previously, we developed a preliminary prototype of a microcirculation model, 16 which was composed of a pneumatic micro-peristaltic pump (heart), dialysis component using a dialysis membrane (renal corpuscle), and cell culture chamber (drug target) to mimic the excretion process. This model was, however, a preliminary proof-of-concept model with very low efficiency. Because the microdevice used a microcirculation model, only one bioassay could be performed at a time.
Here, we propose a multichannel dialysis chip that is able to drive three dialysis systems simultaneously with a micropump. The multichannel dialysis chip realizes three simultaneous bioassays of an anticancer agent, thio-TEPA 17 or docetaxel. 18 
Experimental

Fluidic operations
Three pneumatic control channels (height: 800 μm; width: 950 μm) were positioned across the three circulation channels to simultaneously circulate sample solutions in the three circulation channels. Compressed air was divaricated with three solenoid valves (V100 series; SMC, Tokyo, Japan) and then brought into the control channels at 0.08 MPa. The solenoid valves were controlled with a switching transistor circuit and their drive frequencies were controlled by Raspberry Pi's program (Model B; Raspberry Pi Foundation, Cambridge, UK). To estimate the flow rate in the microchannel, a suspension of fluorescent microbeads (Fluoresbrite YG Microspheres 1.00 μm; Polysciences, Warrington, PA, USA) was circulated with the micropump, while the liner flow rate was measured by particle image velocimetry. The flow rate was calculated from the time required to move a distance of 2 mm (n = 5).
To mimic ultrafiltration in the renal corpuscle, dialysis membranes were used to separate the circulation and the dialysate channels. The sample solutions in the circulation channels were circulated by the micropump and the dialysate solutions were infused into the dialysate channels with a syringe pump (KDS230; KD Scientific, Holliston, MA, USA).
Anticancer test
To estimate anticancer activities, the cell death rate was measured by live/dead staining with calcein-AM and propidium iodide (Wako Pure Chemical, Osaka, Japan). The number of live cells (green) and dead cells (red) were counted using a fluorescence microscope IX71 (Olympus, Tokyo, Japan).
Results and Discussion
Multichannel dialysis chip
The microdevice had three sets of dialysis systems, each of which consisted of three independent circulation channels with a common micropump (Fig. 1) . Each dialysis system was composed of a pneumatic micropump (heart), dialysis unit (renal corpuscle), cell culture chamber (drug target), and circulation and dialysate channels.
The micropump simultaneously circulated a medium containing a sample drug in the three circulation channels (Fig. 1a) . Free small drugs were expected to be excreted through the dialysis membrane, while macromolecule drugs and drugs bound to proteins remained in the circulation channels (Fig. 1b) . The target cells of the drug were cultured in the culture chambers (Fig. 1c) .
Bonding between the PDMS sheets and the dialysis membrane was insufficient. To prevent solution leakage from the three dialysis components, a leak protection channel was constructed around the dialysis units (Fig. S1, Supporting Information) . The leak protection channel was filled with SU-8 and then exposed to UV (for 300 s) to solidify the SU-8. No leakage of the solutions from the channels was found in the improved device during the cell culture and assay procedures.
Micropump operation
The flow rate of each circulation channel of the multichannel dialysis chip was measured. The average flow rate was 7.4 μL/min (standard deviation, 0.2 μL/min) when the drive frequency of the pump was 2.0 Hz.
To control the circulation flow rate, the drive frequency of the solenoid valves was changed using the Rasberry Pi's program. The correlations between the circulation flow rate and the drive frequency of the pump are shown in Fig. S2 (Supporting Information). As the drive frequency increased, the circulation flow rate also increased.
Controllable flow rates were 0.3 -7.4 μL/min. The inter-channel difference of the flow rates was thought to be small enough. The following experiments were performed in triplicate. 
Dialysis experiments
To evaluate the dialysis performance of the microdialysis units, fluorescein (380 Da) or fluorescein isothiocyanate (FITC)-albumin (68 kDa) was circulated in the circulation channel and DMEM was circulated in the dialysate channel.
The concentrations of the solutes were estimated from their fluorescence intensities in the circulation channel.
The results of the dialysis experiments are shown in Fig. 2 . The fluorescein was gradually excreted into the dialysate channel through the dialysis membrane, while the FITC-albumin remained in the circulation channel. The inter-channel difference of the excretion rates was small. These results indicate that the system has the ability to eliminate only small molecules from the circulation channel.
The dialysis experiments were successfully performed in triplicate. The dialysis rate was of little relevance to the circulation flow rate (data not shown).
MCF-7 cell culture
To assay anticancer activity, MCF-7 cells were cultured in the culture chambers. The medium in the circulation channel was circulated at the pump drive frequency of 2 Hz, while fresh medium was infused into the dialysate channel at 42 μL/h with a syringe pump. The cell death rate was <3%, and the standard division rate was 1% after the 72-h culture period (Fig. 3) . No apparent difference in the death rate was found among the three channels (data not shown).
Bioassay of anticancer agents with the system
Docetaxel and thio-TEPA were selected as the anticancer agents for evaluating the microsystem. The plasma protein binding rate of docetaxel was >90%, while that of thio-TEPA was <15%; docetaxel rarely passes through the renal corpuscle, while thio-TEPA is easily excreted. 19, 20 Docetaxel or thio-TEPA dissolved in DMEM with 10% FBS was circulated throughout the circulation channel to assay its anticancer activity with the system.
To compare the bioassay results obtained with the multichannel system to those with the single channel system, an anticancer assay of docetaxel or thio-TEPA was performed using a singlechannel dialysis chip. The volume and shape of the singlechannel system were the same as those of the multichannel system.
In the non-dialysis condition, the cell death rate was >60% for both docetaxel and thio-TEPA (Fig. 4a) . In the dialysis condition, docetaxel caused a cell death rate >60%, while that of thio-TEPA was <10% (Fig. 4b) . From these results, we concluded that docetaxel remained in the circulation channel and that thio-TEPA was excreted from the circulation channel to the dialysate channel. These results were consistent with the natures of the drugs.
A comparison of the single-and multichannel systems in the anticancer assay is shown in Fig. 4 . These results confirmed that the multichannel dialysis chip showed similar reproducible and reliable results to those of the single-channel system but with higher throughput.
Conclusions
Here, we developed a multichannel dialysis microchip to mimic the excretion portion of the ADME process. This device realized a control of flow rate of three channels with a micropump and measured the excretion of small molecules from the dialysis components in parallel. Anticancer tests using this model considered both the serum protein-binding nature and the drug activity.
Compared with the conventional methods for evaluating the excretion process, the present model is ethically more preferable than animal experiments and more sophisticated than in vitro equilibrium dialysis and ultrafiltration methods. Furthermore, throughput of the bioassay was superior to that of our previous model due to the parallel circulation. Three parallel experiments were realized with the developed chip, and more integration may be realized in principle.
With its ability to optimize various conditions such as excretion rate, this model may contribute to the drug discovery field in the near future.
